Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/21/2902220/0/en/Ocugen-Announces-Data-and-Safety-Monitoring-Board-Approves-Enrollment-in-High-Dose-Cohort-3-in-GARDian-Study-for-Stargardt-Disease.html
https://www.globenewswire.com/news-release/2024/06/20/2901513/0/en/Ocugen-Inc-Announces-First-Patient-Dosed-in-Phase-3-liMeliGhT-Clinical-Trial-for-OCU400-First-Gene-Therapy-in-Phase-3-with-a-Broad-Retinitis-Pigmentosa-Indication.html
https://www.globenewswire.com/news-release/2024/05/31/2891519/0/en/Data-and-Safety-Monitoring-Board-Approves-Simultaneous-Enrollment-in-Cohort-3-and-Phase-2-Initiation-in-OCU410-ArMaDa-study-for-Geographic-Atrophy.html
https://www.globenewswire.com/news-release/2024/05/29/2889724/0/en/Ocugen-to-Present-at-BIO-International-Convention-2024.html
https://www.globenewswire.com/news-release/2024/05/28/2888898/0/en/Ocugen-Set-to-Join-Russell-3000-Index-Effective-June-28-2024.html
https://www.globenewswire.com/news-release/2024/05/20/2884757/0/en/Ocugen-Announces-CSO-to-Present-on-Modifier-Gene-Therapy-at-International-Society-for-Cell-Gene-Therapy-2024.html
https://www.globenewswire.com/news-release/2024/05/15/2882235/0/en/Ocugen-Announces-Dosing-Completion-of-Subjects-with-Stargardt-Disease-in-Cohort-2-of-Phase-1-2-GARDian-Clinical-Trial-of-OCU410ST-A-Modifier-Gene-Therapy.html
https://www.globenewswire.com/news-release/2024/05/14/2881343/0/en/Ocugen-Provides-Business-Update-with-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/10/2879828/0/en/Ocugen-Announces-Distribution-of-Series-C-Preferred-Stock-to-Holders-of-its-Common-Stock.html
https://www.globenewswire.com/news-release/2024/05/10/2879562/0/en/Ocugen-to-Present-at-May-2024-Investor-Conferences.html